These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 18162241)

  • 1. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
    Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
    Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HPV vaccination: principles, results and future perspectives].
    Rouzier R; Uzan C; Collinet P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
    J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.